AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01271231
Drug: Scaling and root planing plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
Trial: NCT01271231
Drug: Scaling and root planing plus azythromycin
RxNorm normalized name: rauwolfia alkaloids, whole root and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
Trial: NCT01271231
Drug: Prophylaxis plus azythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
Trial: NCT00713154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
Trial: NCT02231580
Drug: BN82451B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN82451B capsule
Trial: NCT02231580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT02603497
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03673072
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Can be selected by Investigator's Choice
Trial: NCT02353598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
Trial: NCT03121547
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium tablet
Trial: NCT00604331
Drug: Pyruvate
RxNorm normalized name: Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
Trial: NCT00149084
Drug: Lansoprazole, clarithromycin, amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01270711
Drug: Study Drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non interventional study - usage as per usual care
Trial: NCT02298946
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m(2) IV on day 0.
Trial: NCT00140920
Drug: MK0966; rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00140920
Drug: Comparator: diclofenac 2x 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03717454
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication will continue if DA causes tumors to shrink.
Trial: NCT03555994
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0382 administered subcutaneously
Trial: NCT03555994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously
Trial: NCT03110510
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
Trial: NCT03110510
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200 mg/m2
Trial: NCT03655197
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
Trial: NCT02544763
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT02544763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT01887197
Drug: inhaled hypertonic saline (7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulized hypertonic saline (7%)
Trial: NCT02658188
Drug: ASP8825
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01346917
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
Trial: NCT03066518
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00619801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
Trial: NCT03985514
Drug: Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
Trial: NCT02742324
Drug: Ruxolotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
Trial: NCT01320462
Drug: Smoking cessation counselling group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
Trial: NCT02989025
Drug: 17 OHPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
Trial: NCT01961180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02481141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02577575
Drug: Saline Nasal Spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Trial: NCT00913835
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
Trial: NCT01754740
Drug: Uréia
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months.
Trial: NCT01754740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
Trial: NCT04083079
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
Trial: NCT01685996
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02021409
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
Trial: NCT01808612
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01808612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03038646
Drug: MIN-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00356642
Drug: GW842470X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW842470X will be available as a yellow smooth water-in-oil cream.
Trial: NCT00112385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
Trial: NCT01003964
Drug: IP
RxNorm normalized name: GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
Trial: NCT01003964
Drug: GP
RxNorm normalized name: GPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
Trial: NCT04112368
Drug: Estradiol Transdermal Patch 0.1 mg/24 hrs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
Trial: NCT04112368
Drug: Inactive Clear Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Trial: NCT04112368
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Trial: NCT01166178
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg once a year via intravenous infusion
Trial: NCT00356642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
Trial: NCT01166178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to zoledronic acid once a year via intravenous infusion
Trial: NCT01782664
Drug: 100 mg GSK2586184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Trial: NCT01782664
Drug: 200 mg GSK2586184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Trial: NCT01782664
Drug: 400 mg GSK2586184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Trial: NCT01782664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to be taken twice daily with food for up to 84 days.
Trial: NCT01082965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04037397
Drug: Anti Arrhythmics
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
Trial: NCT01286012
Drug: Placebo: Conventional liquid bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
Trial: NCT01286012
Drug: Erythrocyte Stimulating Agent (ESA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
Trial: NCT06690450
Drug: Venofer® 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes
Trial: NCT06690450
Drug: Venofer® 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
Trial: NCT01286012
Drug: Intravenous (IV) Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
Trial: NCT00196417
Drug: Standard heparin (UFH) versus certoparin (LMWH)
RxNorm normalized name: certoparin
DrugBank: Certoparin (DB09261)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02174237
Drug: LNP1892
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of two strengths (5 and 25 mg)
Trial: NCT02174237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02447406
Drug: AZD6094
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02051387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656695
Drug: Iminoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
Trial: NCT03607110
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sedation drugs
Trial: NCT02180672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One spray per nostril, per day.
Trial: NCT01963832
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01963832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02837952
Drug: FDC IBU/APAP 250 mg/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC IBU/APAP 250 mg/500 mg
Trial: NCT02837952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00003907
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Trial: NCT01557569
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
Trial: NCT01108705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0mg, once daily, until disease progression or toxicity
Trial: NCT03376854
Drug: Neuromuscular Blocking Agents
RxNorm normalized name: NEUROMUSCULAR BLOCKING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
Trial: NCT00077285
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03556007
Drug: LY3471851
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Trial: NCT03556007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Trial: NCT04099927
Drug: SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0410 monotherapy,given intravenously
Trial: NCT00077285
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04469114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
Trial: NCT03879655
Drug: VTS-270
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IT via LP infusion of VTS-270
Trial: NCT00353119
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received placebo subcutaneously twice weekly
Trial: NCT02642614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02642614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For blinding purposes
Trial: NCT00254540
Drug: SU011248 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
Trial: NCT02529514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 7 days at 10 pm every day
Trial: NCT03439072
Drug: G-Pen
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Trial: NCT03497702
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m2 IV every 3 weeks for 4 cycles
Trial: NCT03497702
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m2 IV every 3 weeks for 4 cycles
Trial: NCT00934154
Drug: Melphalan+Prednisolone
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 2 mg, Prednisolone 16 mg
Trial: NCT00229099
Drug: GerEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00266032
Drug: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
Trial: NCT00266032
Drug: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
Trial: NCT00266032
Drug: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
Trial: NCT04019704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
Trial: NCT01918358
Drug: Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01918358
Drug: Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01918358
Drug: Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01918358
Drug: Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01918358
Drug: Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01918358
Drug: Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00361855
Drug: NX-CP105
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01108133
Drug: 10 mg HydrocortisoneHöchst
RxNorm normalized name: HYDROCORTISONE 10 g in 100 g TOPICAL OINTMENT [HydrocortisoneLotion]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
Trial: NCT01108133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00225160
Drug: acetyl L-carnitine
RxNorm normalized name: Nature's Way Acetyl L-Carnitine Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05318443
Drug: SIBP04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
Trial: NCT02951819
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
Trial: NCT04634136
Drug: Full-spectrum Medical Canabis Product (HemPhar)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active substance
Trial: NCT04634136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo